Solitomab Biosimilar - Anti-CD3E, EpCAM mAb - Research Grade
Source
CAS 1005198-65-1
Species
Mus musculus
Expression system
Mammalian
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Solitomab,MT110,CD3E, EpCAM,anti-CD3E, EpCAM
Reference
PX-TA1282
Note
For research use only. Not suitable for human use.
Isotype
(scFv-kappa-heavy)-(scFv-heavy-kappa)
Clonality
Monoclonal Antibody
Description of Solitomab Biosimilar - Anti-CD3E, EpCAM mAb - Research Grade
General information on Anti-CD3E/EpCAM[Homo sapiens] (Solitomab) Monoclonal Antibody
Solitomab has been investigated for the treatment of Lung Cancer, Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer.
Enhanced anti-tumor activity by Zinc Finger Repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs, Marion David, Phillip Schiele, Davide Monteferrario, Gaëlle Saviane, Angélique E. Martelli, Coralie F. Dupont, Caroline Jeanneau, Irène Marchetti, Satish K. Tadi, Julia Vahldick, Lynn N. Truong, Yuanyue Zhou, Igor M. Sauer, Wenzel Schöning, Il-Kang Na, Andreas Reik, Marco Frentsch, Maurus de la Rosa, David Fenard, bioRxiv 2024.10.11.613893; doi: https://doi.org/10.1101/2024.10.11.613893
Vele –
Great product!